Integrated BioTherapeutics Inc. (IBT), a Maryland biotechnology company specializing in emerging infectious diseases, announced today the receipt of a contract valued at up to $16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for treatment of Marburg virus disease (MVD). MVD is caused by either of two marburgviruses, Marburg virus and Ravn virus, and has reemerged several times since it was initially described in 1967. IBT-T03H, discovered in collaboration with the University of Maryland, has been shown in preclinical studies to be protective against both Marburg and Ravn virus.
Rockville’s Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease
Published on :